Novel gp120 of HIV-1 Antagonist

Novel potent and specific inhibitor of the UNC119-Src interaction, binding to UNC119 in cells, and inducing redistribution of Src to endomembranes and reduction of activating Src autophosphorylation on Y419

Novel ASCT2 inhibitor

Cell-permeable fluorometric zinc sensor

Non-competitive AMPA receptor antagonist

Type III progesterone receptor antagonist with enhanced antiproliferative properties

Novel oral multitarget tumour growth inhibitor

Novel potent inhibitor of factor Xa (FXa)

Novel dual mordulator of nNOS-PSD-95 interaction and GABA A receptor

Novel potent and selective BRD4 bromodomain 1 (BD1) inhibitor

Novel potent and selective BRD4 bromodomain 1 (BD1) inhibitor

Novel β-catenin/B-cell lymphoma 9 (BCL9) inhibitor, disrupting the β-catenin/BCL9 protein-protein interaction (PPI) with a Ki of 0.96 μM and without affecting the β-catenin/E-cadherin interaction in living cells, displaying good selectivity for β-catenin/

Novel potent and highly selective inhibitor of wild-type and mutant versions of EZH2

ATP-sensitive potassium channel-blocker; Eukalemic diuretic

Non-steroidal pure antioestrogen

5-Lipoxygenase (5-LO) inhibitor

K-Channel opener (PCO) activating predominantly KATP channels in vitro to relax bladder detrusors

Selective nonpeptide, NK-2 receptor (NK-2R) antagonist

Potassium channel opener

Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3)

Novel antidiabetic agent for the treatment of type 2 diabetes mellitus (DM)

Inducer of functional angiogenesis through increased H 2 S availability